“What did I do wrong?” I cried out.My surgeon spoke in subdued tones, quoting statistics and survival rates, but I stopped listening. Fear drowned out his ...

Cabometyx (cabozantinib) provided a survival benefit without disease progression compared with placebo in patients with advanced neuroendocrine tumors ...

The FDA approved Braftovi plus Mektovi for metastatic lung cancer, offering this patient population another targeted treatment option. When the Food and ...

I was different. I didn’t fit into my childhood family. Although my dad tried to accept me as I was, my mother didn’t. I suffered from lots of sadness as a ...

Frontline tehrapy with Rybrevant (amivantamab-vmjw) plus Leclaza (lazertinib) reduced the risk of disease progression or death by 30% versus Tagrisso ...

Pluvicto improved progression-free survival in certain patients with prostate cancer, recent research showed. Treatment with Pluvicto (177-Lu-PSMA-617) ...

Patients with high-risk, early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer treated with neoadjuvant (presurgical) Keytruda ...

Patients with hormone receptor-positive HER2-low or HER2-negative metastatic breast cancer tended to have improved progression-free survival when being ...

In the fall of 2022, I was diagnosed with Stage 2, non-specific, non-Hodgkins Lymphoma. I would spend the next six months in and out of the hospital for ...

Cancer is a journey that no one ever plans to embark upon, but when life takes an unexpected turn, we have no choice but to navigate this challenging path. ...